Xeris Biopharma Holdings XERS
NASDAQ XERS
$16.52 +0.69 (+4.36%)
At close: Nov 11, 2026 · 4:00 PM EST

Xeris Biopharma Holdings (XERS) Short term Debt (2024 - 2026)

Updated

Analysis

Xeris Biopharma Holdings (XERS) Short term Debt (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Xeris Biopharma Holdings 2.89 Bn 2.41 Bn 94.80 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 63.78 Mn
Mar 31, 2025 11.96 Mn
Dec 31, 2024 15.10 Mn
Sep 30, 2024 15.06 Mn
API Access

Xeris Biopharma Holdings Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=XERS&period=max&api_key=YOUR_API_KEY